What is the recommended dosing for Lexapro (escitalopram)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosing for Lexapro (Escitalopram)

The recommended initial dose of Lexapro (escitalopram) is 10 mg once daily for most adults, with a maximum recommended dose of 20 mg daily. 1

Initial Dosing

  • Adults with Major Depressive Disorder (MDD):

    • Start with 10 mg once daily
    • May increase to 20 mg after a minimum of one week if clinically indicated
    • FDA-approved studies showed both 10 mg and 20 mg were effective, but failed to demonstrate greater benefit of 20 mg over 10 mg 1
  • Adults with Generalized Anxiety Disorder (GAD):

    • Start with 10 mg once daily
    • May increase to 20 mg after a minimum of one week if needed 1
  • Special Populations:

    • Elderly patients: 10 mg/day recommended
    • Patients with hepatic impairment: 10 mg/day recommended
    • Patients with mild to moderate renal impairment: No dosage adjustment necessary
    • Patients with severe renal impairment: Use with caution 1

Administration

  • Can be taken in the morning or evening
  • Can be taken with or without food 1
  • Once-daily dosing is sufficient due to the long half-life of escitalopram

Duration of Treatment

  • Acute Phase: 4-8 weeks is typically needed for full therapeutic trial 2
  • Maintenance Phase:
    • For MDD: Continue treatment for at least 4-12 months after response to acute episode 2
    • For GAD: Efficacy beyond 8 weeks has not been systematically studied, but maintenance treatment is often recommended 1

Dose Titration

  • Increase dose using increments of initial dose every 5-7 days until therapeutic benefits or significant side effects become apparent 2
  • After successful treatment period (typically 9 months), dosage reduction can be used to reassess the need for continued medication 2

Discontinuation

  • Gradual reduction rather than abrupt cessation is recommended
  • Monitor for discontinuation symptoms (dizziness, sensory disturbances, anxiety, sleep disturbances)
  • If intolerable symptoms occur during discontinuation, resuming the previously prescribed dose may be considered, then continue decreasing at a more gradual rate 1

Common Pitfalls and Considerations

  1. Avoid abrupt discontinuation: This can lead to withdrawal symptoms. Taper the medication over 10-14 days to limit withdrawal symptoms 2, 1

  2. Screen for bipolar disorder: Prior to initiating treatment, screen patients for personal or family history of bipolar disorder, mania, or hypomania to avoid triggering manic episodes 1

  3. Drug interactions: Escitalopram may prolong the half-life of other drugs by inhibiting cytochrome P450 isoenzymes, though it has less effect on metabolism of other medications compared to other SSRIs 2, 3

  4. QT prolongation: The maximum recommended dose is 20 mg due to dose-dependent QT interval prolongation 1

  5. Early response monitoring: Assess efficacy and safety at least monthly for the first 3 months and at least quarterly thereafter. Early responders (>5% weight loss after 3 months) tend to have improved long-term outcomes 2

Escitalopram has demonstrated efficacy in both short-term and long-term studies, with research showing continued improvement in depression symptoms over 12 months of treatment 4. It is generally well-tolerated with a favorable side effect profile compared to many other antidepressants 2, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Anxiety Disorders

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Escitalopram in the long-term treatment of major depressive disorder.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.